Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)
Plain-language summary
This trial is testing Brentuximab Vedotin (Bv) for patients with anaplastic large cell lymphoma (ALCL) or cutaneous T-cell lymphoma (CTCL) at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to treatment groups, and neither patients nor doctors know which treatment is being given. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.
Who can join (key eligibility)
- Age 18 Years or older
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Brentuximab Vedotin (Bv) (DRUG): Patients will receive brentuximab vedotin intravenously at a dose of 1.8 mg/kg every 3 weeks for a total of 16 cycles. | Lisaftoclax (APG-2575) (DRUG): Patients will receive Brentuximab Vedotin (1.8 mg/kg, IV, q3w, 16 cycles). Starting from cycle 6, oral Lisaftoclax will be added (600 mg daily on days 1-10 of each 21-day cycle, for 9 cycles, with a daily dose ramp-up in the first cycle).
Brentuximab Vedotin (Bv), Lisaftoclax (APG-2575)
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details